Interventional Cardiology

K-Clip shows high success rates, improved quality of life, and sustained TR reduction in severe tricuspid regurgitation patients.

3D-Vena Contracta Area (VCA) predicts one-year survival after mitral TEER, guiding better clinical decisions and outcomes.

Clopidogrel reduces thrombotic and bleeding risks over aspirin after PCI, effective regardless of bleeding risk or complexity.

T-TEER improves patient outcomes and quality of life in severe tricuspid regurgitation compared to medical therapy alone.

Bicaval TricValve shows safety, improves symptoms, and reduces hospitalisations in patients with severe tricuspid regurgitation.

The MiCLASP study highlights the PASCAL system’s sustained safety and effectiveness in reducing mitral regurgitation at two years.

A multicentre study shows safety and success rates for the transfemoral J-valve in severe aortic regurgitation.

Study confirms transcatheter tricuspid-valve replacement improves symptoms, quality of life in severe tricuspid regurgitation patients.